Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanxin Qiwei Wan is a traditional Mongolian and Chinese medicine formulation developed by Mengyao Pharmaceutical for the treatment of cardiovascular conditions, including atherosclerosis and coronary heart disease. The formulation is a combination of seven botanical ingredients: Myristicae semen (Myristica fragrans), Choerospondiatis fructus (Choerospondias axillaris), Santali albi lignum (Santalum album), Codonopisis radix (Codonopsis pilosula), Kaempferiae Rhizoma (Kaempferia galanga), Dalbergiae odoriferae lignum (Dalbergia odorifera), and Hippophae Fructus (Hippophae rhamnoides). It is administered orally and is officially recognized in the Drug Standards of the Ministry of Health of the People's Republic of China. The therapeutic effects are attributed to the synergistic action of its components, which are thought to provide cardioprotective benefits through antioxidant and anti-inflammatory pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guanxin Qiwei Wan.